Awiqli® is the commercial brand name of Insulin Icodec Injection. Changchong is the Chinese pinyin brand name. It is a long-acting basal insulin analogue, which binds to insulin receptors to regulate glucose metabolism and achieve sustained glycemic control.
Main Indications
Treatment of adult patients with type 1 diabetes mellitus and type 2 diabetes mellitus to improve glycemic control.
Clinical Research
Phase 3 clinical studies demonstrated that once-weekly insulin icodec achieved comparable HbA1c reduction versus once-daily basal insulin. It showed a low risk of hypoglycemia and brought convenience for patients by reducing injection frequency.
Common Side Effects
Hypoglycemia, injection site reactions;
Other common reactions: weight gain, peripheral edema. Rare serious adverse events include severe hypersensitivity reactions.
Approval Status in China
Original drug Awiqli® (Insulin Icodec Injection) was officially approved for marketing in China in 2024, with the specification of 700 units/mL, 1mL per pen. It is currently a prescription drug.
Buy Awiqli (Insulin Icodec Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
